Company Announcements

The use of LuerVax® and Spray Divider™ support Aptar’s commitment to advancing drug delivery and next-generation vaccine development, backed by comprehensive regulatory and technical expertise

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Jan. 13, 2026-- AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, announced that its innovative nasal vaccine delivery solutions, LuerVax® and Spray Divider™, are being utilized in CastleVax’s Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. This milestone underscores Aptar Pharma’s commitment to advancing vaccine delivery technologies and supporting the development of novel immunization strategies. The Phase II study of CVAX-01 is assessing the safety, tolerability and systemic and mucosal immune response of CastleVax’s intranasal COVID-19 vaccine compared to an FDA-approved injectable mRNA vaccine. Around 200 U.S. adults, including high-risk individuals and those over 65, will be followed for six months to evaluate whether nasal delivery can provide strong mucosal immunity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113832919/en/

Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate

This collaboration reinforces Aptar’s position as a trusted partner in the evolving landscape of nasal vaccine delivery systems and next-generation vaccines. By leveraging its deep expertise in regulatory pathways, technical support, and innovative device design, Aptar supports pharmaceutical partners in their efforts to accelerate development and bring cutting-edge solutions to market.

Aptar supports customers throughout the nasal drug development journey: from system design and formulation compatibility to clinical trial support and regulatory guidance. Its Pharma Services platform offers expertise in combination products, device/formulation optimization, and critical testing such as extractables and leachables, helping partners manage development risks and support efforts to accelerate time-to-market.

“Our collaboration on CastleVax’s Phase II trial reflects why leading innovators choose Aptar as their trusted partner for next-generation medicine development and advanced drug delivery,” said Alex Theodorakis, President, Aptar Pharma Prescription. “By offering comprehensive regulatory guidance and technical support, we help our customers navigate complexity with confidence and accelerate the delivery of life-changing therapies to patients worldwide.”

About Aptar

Aptar is a global leader in drug delivery and consumer product, dispensing, dosing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements, including regarding the use of LuerVax® and Spray Divider™ in third-party intranasal vaccine clinical development activities. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: risks related to clinical development activities conducted by third parties; development and commercialization risks; customer adoption; regulatory requirements and compliance; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260113832919/en/

Aptar Investors Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407

Aptar Pharma Media Contact:
Ciara Jackson
ciara.jackson@aptar.com
+49 151 1951 6502

Aptar Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815 479 5671

Source: AptarGroup, Inc.